Serum markers, conventional Doppler echocardiography and two-dimensional systolic strain in the diagnosis of chemotherapy-induced myocardial toxicity;Integración de marcadores humorales, ecocardiograma doppler convencional y strain bidimensional sistólico en la detección de toxicidad miocárdica secundaria a la quimioterapia

Revista Argentina de Cardiologia

Volumn 81, Issue 2, 2013, Pages 151-158

  Baratta, Sergio ^a   Damiano, Mario A ^a   Marchese, María L ^a   Trucco, José I ^a   Rizzo, Manglio M ^a   Bernok, Flavia ^a   Chejtman, Demián ^a   Olano, Daniel ^a   Rojas, Mercedes ^a   Hita, Alejandro ^a  

^a UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

Cardiotoxicitiy; Chemotherapy; Strain imaging

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOXANTRONE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB; TROPONIN T; VINCRISTINE;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VOLUME; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MALIGNANT NEOPLASTIC DISEASE; OBSERVER VARIATION; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TWO DIMENSIONAL SYSTOLIC LONGITUDINAL STRAIN; TWO DIMENSIONAL SYSTOLIC RADIAL STRAIN;

EID: 84878821848     PISSN: 00347000     EISSN: 18503748     Source Type: Journal    
DOI: 10.7775/rac.es.v81.i2.2300     Document Type: Article

References (40)

1. Yeh ET, Tong AT, Lenihan DJ, Yusuf S W, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-3131. http://doi.org/d8dv7m
2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-2879. http://doi.org/cqqfwm
3. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999;17:2237-2243.
4. Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 2006;94:1016-1020. http://doi.org/dbjkxq
5. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007;116:2216-2233. http://doi.org/cpkbhp
6. Ta Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon R P, et al. Assessment of cardiac dysfunction in a random ized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overex- pressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819. http://doi.org/cvx9hz
7. Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006;7:237-243.
8. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754. http://doi.org/fjkcd2
9. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318-326. http://doi.org/bfv5jt
10. Sawaya H, Sebag IA, Plana JC, Januzzi JL, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375-1380. http://doi.org/b4szxp
11. Urbanova D, Urban L, Danova K, Simkova I. Natriuretic pep-tides: biochemical markers of anthracycline cardiac toxicity? Oncol Res 2008;17:51-58.
12. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects of left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011;148:194-198. http://doi.org/bc6jrp
13. Martin M, Esteva FJ, Alba E, Khandheria B, Perez-Isla L, Garcia Saenz JA, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009;14:1-11. http://doi.org/dwmhwv
14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463. http://doi.org/b92m9w
15. Shimizu G, Zile MR, Blaustein AS, Gaasch WH. Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements. Circulation 1985;71:266-272. http://doi.org/bw83fh
16. Marwick TH, Leano RL, Brown J, Sun J P, Hoffmann R, Lysy-ansky P, et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range. JACC Cardiovasc Imaging 2009;2:80-84. http://doi.org/dbxbnx
17. Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother 2008;42:99-104. http://doi.org/fd8btx
18. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-1454.
19. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109-1118.
20. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-e235. http://doi.org/cd7mzm
21. Neilan TG, Jassal DS, Perez-Sanz TM, Raher MJ, Pradhan AD, Buys ES, et al. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 2006;27:1868-1875. http://doi.org/dpbm9k
22. Ganame J, Claus P, Eyskens B, Uyttebroeck A, Renard M, D'Hooge J, et al. Acute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol 2007;99:974-977. http://doi.org/cdtpw4
23. Jurcut R, Wildiers H, Ganame J, D'Hooge J, De Backer J, Denys H, et al. Strain rate imaging detects early cardiac effects of pegylated lipo-somal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 2008;21:1283-1289. http://doi.org/b28wwz
24. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 2009;158:294-301. http://doi.org/cnzgxc
25. Stoodley P W, Richards DA, Hui R. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr 2011;12:945-952. http://doi.org/bsr39t
26. rd july).
27. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-1301. http://doi.org/cq4npk
28. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloi-dosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr 2004;17:36-44. http://doi.org/cnzw5r
29. Serri K, Reant P, Lafitte M, Berhouet M, Le Bouffos V, Roudaut R, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;47:1175-1181. http://doi.org/cpsrzm
30. Anderson RH, Ho SY, Redmann K, Sanchez-Quintana D, Lunken-heimer P P. The anatomical arrangement of the myocardial cells making up the ventricular mass. Eur J Cardiothorac Surg 2005;28:517-525. http://doi.org/d68hdp
31. Argyle RA, Ray SG. Stress and strain: double trouble or useful tool? Eur J Echocardiogr 2009;10:716-722. http://doi.org/ffvb9x
32. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-2270. http://doi.org/crp56f
33. Tsai HR, Gjesdal O, Wethal T, Haugaa KH, Fossa A, Fossa SD, et al. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. Am J Cardiol 2011;107:472-477. http://doi.org/fqq7nx
34. Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010;96:701-707. http://doi.org/bjfrzt
35. Nisticò C, Bria E, Cuppone F, Fornier M, Sperduti I, Carpino A, et al. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. Anticancer Drugs 2007;18:687-692. http://doi.org/fpcgzc
36. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92-98. http://doi.org/bwhfpc
37. Nagy AC, Tolnay E, Nagykalnai T, Forster T. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI. Neoplasma 2006;53:511-517.
38. Pudil R, Horacek JM, Strasova A, et al. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. Exp Oncol 2008;30:160-162.
39. Stoddard M F, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992;20:62-69. http://doi.org/fk8f5k
40. Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging 2013;14:228-234. http://doi.org/ksz